| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8771609 | The Journal of Urology | 2018 | 6 Pages |
Abstract
Enzalutamide antitumor activity was maintained in patients with hormone naïve prostate cancer at 3 years. Overall bone mineral density, global health status and safety results were similar to those at 2 years.
Keywords
PSABMDhNPCADTQLQ-C30MDV 3100mCRPCBALPEORTCTEAEProstate specific antigenBone densityBone mineral densityandrogen deprivation therapyEuropean Organisation for Research and Treatment of CancerMetastatic castration resistant prostate canceradverse eventProstatic neoplasmsprostate-specific antigenPartial responsecomplete response
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, Axel Heidenreich, Peter Iversen, Johan Braeckman, Jiri Heracek, Benoit Baron, Andrew Krivoshik, Mohammad Hirmand, Matthew R. Smith,